1Mak V, Harem J, Chhanabhai M, et al. Survival of patients with periph- eral T-cell lymphoma after first relapse or progression : spectrum of dis- ease and rare long-term survivors [ J ]. J Clin Oncol, 2013,31 ( 16 ) : 1970-1976.
2Vose JM.Status of ongoing collaborative efforts.Semin Hematol,2010,47:S18-20.
3Gutierrez M,Chabner BA,Pearson D,et al.Role of a doxorubicincontaining regimen in relapsed and resistant lymphomas:an 8-year follow-up study of EPOCH.J Clin Oncol,2000,18:3633-3642.
4Nagajothi N,Dham SK,Gelfand Y,et al.Treatment of AIDSassociated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.J Natl Med Assoc,2007,99:799-801.
5Assouline S,Meyer RM,Infante-Rivard C,et al.Development of adapted RECIST criteria to assess response in lymphoma and their comparison to the International Workshop Criteria.Leuk Lymphoma,2007,48:513-520.
6Franklin HR,Simonetti GP,Dubbelman AC,et al.Toxicity grading systems.A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting.Ann Oncol,1994,5:113-117.
7Vose JM.Peripheral T-cell non-Hodgkin's lymphoma.Hematol Oncol Clin North Am,2008,22:997-1005.
8Foss FM.Enhancing existing approaches to peripheral T-cell lymphoma.Semin Hematol,2010,47:S8-10.
9Wilson WH,Bryant G,Bates S,et al.EPOCH chemotherapy:toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma.J Clin Oncol,1993,11:1573-1582.
10Wilder DD,Ogden JL,Jain VK.A multicenter trial of infusional etoposide,doxorubicin,and vincristine with cyclophosphamide and prednisone (EPOCH) in patients with relapsed non-Hodgkin's lymphoma.Clin Lymphoma,2001,1:285-292.
